Abstract: Disclosed herein are systems, methods, and devices for sensing touch at a surface. Sensing touch can be achieved while decreasing the number of sensors at a surface as well as data and computation complexity, but maintaining accuracy. Such sensing touch can be achieved via applying excitation and detecting emission waveforms at a surface that are associated with touch at a surface.

Abstract: Disclosed is a method for treating or preventing nephrogenic diabetes insipidus (NDI) in a subject that includes administering to the subject a therapeutically effective amount of a Nuclear factor-erythroid 2-related factor 2 (Nrf2) inducer, thereby treating or preventing the NDI in the subject. The Nrf2 inducer may be a fumarate, a nitro fatty acid, a bardoxolone or sulforaphane. Also disclosed is a pharmaceutical composition comprising (i) a Nuclear factor-crythroid 2-related factor 2 (Nrf2) inducer and (ii) lithium or a lithium salt.

Abstract: Described herein are sensing cannula systems that include a surgical instrument, a detection unit, and a conductive pad having a reference electrode and configured to be placed on the patient at a location outside the patient's body. The surgical instrument can include a cannula (such as a fat grafting cannula) having an electrically conductive distal tip and electrical insulation covering the cannula proximally from the distal tip, wherein the distal tip comprises a first electrode. The detection unit can include electrical circuitry that is electrically coupled to the surgical instrument and the conductive pad and operable to measure an electrical impedance between the first electrode and the reference electrode to determine what type of tissue the distal tip is in.

Abstract: An objective screening platform for mTBI screening includes a vergence testing stimulus generator visible to a subject and configured for presenting visual stimulus to a subject which forms an optical target stimulus for at least one vergence test; at least one data acquisition unit for obtaining objective physiologic responses of the subject unit based upon each of the visual stimulus presented to the subject in each test, wherein the objective physiologic responses for each test include at least one eye position parameter and at least one pupil area parameter; and a controller configured for using at least one eye position parameter and at least one pupil area parameter to screen for the presence of mTBI of the subject.

Abstract: Interferon-?-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C—X—C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.

Abstract: The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A device for removing fat from a body can include a pair of nested hollow members that each has at least one opening and an adjustment means for adjusting the orientation of the nested hollow members from a first configuration to a second configuration to change an amount of overlap between openings in the nested hollow members. The nested members can be deformable to change the shape of the openings.

Abstract: Methods are disclosed for inhibiting esophageal inflammation in a subject, that include administering to the esophagus of the subject with esophageal inflammation a therapeutically effective amount of an extracellular matrix (ECM) hydrogel. Methods are also disclosed for reducing esophageal stricture. Compositions are disclosed that include an esophageal extracellular matrix (ECM) hydrogel.

Abstract: Disclosed herein are embodiments of a polymer-based implant and methods of making and using the same. The polymer-based implant comprises a polymer component and a therapeutic agent. In some embodiments, the polymer-based implant can be used to treat and/or prevent retinal diseases and/or retinopathies. The polymer-based implant exhibits physical properties that provide the ability to safely place the polymer-based implant in an ocular region without undesired diffusion and also to allow for controlled and timely release of the therapeutic agent to a desired region of the ocular region, such as the retina. In particular disclosed embodiments, the polymer-based implant can be used for safe and effective gene therapy.

Abstract: Disclosed herein are various bioreactor devices that mimic the mammalian joint. The bioreactor device can include a series of bioreactor chambers that contain different components of the joint, such as bone, cartilage, synovium, nerve and ligament. At least two different nutrient fluid circulation systems connect subsets of the bioreactor chambers to differentially supply nutrient fluids at concentrations optimized for the tissue that the fluid nourishes. For example, relatively hypoxic fluid can be supplied to synovium and cartilage to mimic oxygenation in the joint compartment, but normoxic fluid can be supplied to the bone and other components that have an arterial supply that provides higher oxygen concentrations. One or more or all of the bioreactor chambers can be supplied with separate inlets through which perturbation agents (such as drugs or other agents) can be introduced to model the effect of the perturbations on different components of the system.

Abstract: A method of monitoring operation of a reactor system includes causing a chemical reaction to occur within an assembly of the reactor system, and measuring a chemical composition of one or more reactants of the chemical reaction with spatial resolution at a plurality of points along a path within the assembly using a sensor system structured to implement distributed sensing. The sensor system includes an optical fiber sensing member provided at least partially within the assembly, wherein the optical fiber sensing member comprises a functionalized optical fiber based sensor device structured to exhibit a change in one or more optical properties in response to changes in the chemical composition of the one or more reactants.

Abstract: The invention relates to an in-utero ventriculoamniotic shunting device that includes a composite shunt tube composed of polymer material, e.g., silicone-based material, and metallic wire, having a bend or curve formed in the length of the shunt tube, with one or more anchors composed of super-elastic wire or mesh, e.g., shape memory alloy wire or mesh structures, attached to the shunt tube, and a one-way passive valve composed of a thin polymer membrane. The anchors are effective to prevent migration and dislodgement of the shunting device following its deployment, and the valve is effective to prevent the backflow of amniotic fluid.

Abstract: The disclosed methods relate to forming microneedle arrays from a production mold that comprises a flexible mold material. The disclosed methods can be used to reproducibly manufacture undercut dissolvable and coated microneedle arrays with various shapes and structures.

Abstract: An energy harvesting device includes a housing (2), a moveable device (12) disposed within the housing and including a first surface including a first material (15) and a second surface including a second material (17), wherein the moveable device is operable to move to bring the first and second surfaces together and apart to cause contact and separation between the first and second materials, a first strap (4) attached to the housing, a second strap (6) coupled to the moveable device, wherein movement of the second strap causes operation of the moveable device, and electronic circuitry (20) structured to harvest energy from the electrical charge generated by the contact between the first and second materials.

Abstract: The invention provides a composition (e.g., pharmaceutical composition) comprising a combination of two or more phages, wherein the phages are two or more of: (a) phage D29; (b) phage Adephagia?41?43; (c) phage Fionnbharth?47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The invention provides a method of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal comprising administering a pharmaceutical composition comprising a combination of two or more phages wherein the phages are two or more of: (a) phage D29; (b) phage Adephagia?41?43; (c) phage Fionnbharth?47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The composition can be administered alone or in combination with one or more antibiotics, wherein the length of treatment is reduced as compared to the length of treatment with one or more antibiotics alone.

Abstract: Disclosed are methods and kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.

Abstract: A method for treating an ocular disorder in a subject comprising administering a therapeutic agent-loaded carrier to an ocular site of the subject in need thereof, wherein the therapeutic agent loaded-carrier provides controlled delivery of the therapeutic agent under conditions suitable for recruiting regulatory T cells to an ocular region of interest or inducing regulatory T cells in an ocular region of interest.

Abstract: A method of characterizing cellular phenotypes includes receiving multi-parameter cellular and sub-cellular imaging data for a number of tissue samples from a number of patients or a number of multicellular in vitro models, performing cellular segmentation on the multi-parameter cellular and sub-cellular imaging data to create segmented multi-parameter cellular and sub-cellular imaging data, and performing recursive decomposition on the segmented multi-parameter cellular and subcellular imaging data to identify a plurality of computational phenotypes. The recursive decomposition includes a plurality of levels of decomposition with each level of decomposition including soft/probabilistic clustering and spatial regularization, and each cell in the segmented multi-parameter cellular and subcellular imaging data is probabilistically assigned to one or more of the plurality of computational phenotypes.

Abstract: A method of managing data during execution of an application for use in a system that includes a host memory, a near memory, and a near device associated with the near memory. The application uses a working set of data that is distributed between the far memory and the near memory. The method includes counting a number of times that the near device accesses a unit of the working set of data from the far memory, determining whether the number of times exceeds a dynamically changing access counter threshold, wherein the dynamically changing access counter threshold is calculated dynamically based on a static threshold that is set for the system, and responsive to determining that the number of times exceeds the dynamically changing access counter threshold, migrating the unit of data from the far memory to the near memory.

Abstract: Disclosed is a method for administering a transgene into a fibroblast in a subject comprising: a) providing a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein said recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide to be expressed in said fibroblast; and b) providing a pharmaceutically acceptable carrier; wherein said HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.